VBIV - VBIワクチン (VBI Vaccines Inc.)

VBIVのニュース

   VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference  2020/10/15 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the management team will discuss VBI-2601, the Company’s vaccine immunotherapeutic candidate in development for a functional cure for hepatitis B (HBV) infection, in a fireside chat at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference on Tuesday, October 20, 20
   VBI Vaccines Announces e-Poster Presentation at The Liver Meeting® 2020  2020/10/08 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract highlighting data from the Phase 3 program evaluating Sci-B-Vac®, the company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, was accepted for e-poster presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting®, on Novembe
   VBI Vaccines to Present at Upcoming Scientific Conferences  2020/09/24 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced upcoming presentations highlighting data from multiple clinical programs – including Sci-B-Vac®, the company’s 3-antigen hepatitis B vaccine; VBI-2900, the company’s coronavirus vaccine program; and VBI-1901, the company’s cancer vaccine immunotherapeutic – at the World Vaccine Congress
   VBI Vaccines Announces Biomarker Data From VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020  2020/09/17 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced additional biomarker data from its ongoing Phase 1/2a study evaluating VBI-1901, the company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM) patients presented in an e-poster at The European Society for Medical Oncology (ESMO) Virtual Congress 2020. Expandin
   VBI Vaccines to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020  2020/09/14 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract highlighting additional biomarker data from the ongoing Phase 1/2a study of VBI-1901, the company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients was selected for an e-poster presentation at The European Society for Medical Oncolo

calendar